Oxidative stress and nitric oxide in autism spectrum disorder and other neuropsychiatric disorders

CNS and Neurological Disorders - Drug Targets

Volumn 15, Issue 5, 2016, Pages 587-596

  Yui, Kunio ^a,b   Kawasaki, Yohei ^c   Yamada, Hiroshi ^c   Ogawa, Shintaro ^d  

^a Ashiya University   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF SHIZUOKA   (Japan)

^d NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

Arachidonic acid; Neuroprotective effects; Neurotoxic effects; Nitric oxide; Oxidative stress; Polyunsaturated fatty acids; Therapeutic potential

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; N METHYL DEXTRO ASPARTIC ACID; NITRIC OXIDE; NITROPRUSSIDE SODIUM; POLYUNSATURATED FATTY ACID; TETRAHYDROBIOPTERIN;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; AUTISM; BIPOLAR DEPRESSION; BIPOLAR DISORDER; COGNITIVE DEFECT; HUMAN; MAJOR DEPRESSION; MITOCHONDRIAL PERMEABILITY; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROMODULATION; NEURONAL MIGRATION DISORDER; NEUROPROTECTION; NEUROPSYCHIATRY; OXIDATIVE STRESS; QUESTIONNAIRE; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; ANIMAL; AUTISM SPECTRUM DISORDER; MENTAL DISORDERS; METABOLISM; NERVE CELL; PHYSIOLOGY;

ANIMALS; AUTISM SPECTRUM DISORDER; HUMANS; MENTAL DISORDERS; NEURONS; NITRIC OXIDE; OXIDATIVE STRESS;

EID: 84974717613     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527315666160413121751     Document Type: Article

References (108)

1. Taylor B, Jick H, Maclaughlin D. Prevalence and incidence rates of autism in the UK: time trend from 2004-2010 in children aged 8 years. BMJ Open 2013; 3(10): e003219.
2. Baron-Cohen S, Lombardo MV, Auyeung B, et al. Why are autism spectrum conditions more prevalent in males? PLoS Biol 2012; 9: e1001081.
3. Durieux AM, Horder J, Mendez MA, et al. Cortical and subcortical glutathione levels in adults with autism spectrum disorder. Autism Res 2016; [Epub ahead of print].
4. Yoshikawa T, Naiyo Y. What is oxidative stress. JMAJ 2002; 45: 271-6.
5. Sharma S, Saxena S, Srivastav K, et al. Nitric oxide and oxidative stress is associated with severity of diabetic retinopathy and retinal structural alterations. Clin Exp Ophthalmol 2015; 43: 429-36.
6. Nasyrova RF, Ivashchenko DV, Ivanov MV, Neznanov NG. Role of nitric oxide and related molecules in schizophrenia pathogenesis: biochemical, genetic and clinical aspects. Front Physiol 2015; 11; 6: 139.
7. Pitsikas N. The role of nitric oxide donors in schizophrenia: Basic studies and clinical applications. Eur J Pharmacol 2015; 766: 106-13.
8. Bloodsworth A, Valerie B, O'Donnell, Bruce A. Freeman. Nitric Oxide Regulation of Free Radical-and Enzyme-Mediated Lipid and Lipoprotein Oxidation. Arterioscler Thromb Vasc Biol 2000; 20: 1707-15.
9. Wegener G, Volk V. Nitric Oxide Synthase Inhibitors as Antidepressants. Pharmaceuticals 2010; 3: 273-99.
10. Ozen A, Ergun E, Oztaş E, et al. Immunohistochemical expression of nitric oxide synthase enzymes (iNOS, eNOS, nNOS) in the estrual and luteal phases of the sexual cycle in the cow oviduct. Anat Histol Embryol 2013; 42: 384-93.
11. Palomba L, Bianchi M, Persichini T, et al. Downregulation of nitric oxide formation by cytosolic phospholipase A2-released arachidonic acid. Free Radic Biol Med 2004; 36: 319-29.
12. Palomba L, Cerioni L, Cantoni O. Arachidonic acid inhibits neuronal nitric oxide synthase elicited by proinflammatory stimuli and promotes astrocyte survival with both exogenous and endogenous peroxynitrite via different mechanisms. J Neurosci Res 2010; 88: 2459-68.
13. Bloodsworth A, O'Donnell VB, Freeman BA. Nitric oxide regulation of free radical-and enzyme-mediated lipid and lipoprotein oxidation. Arterioscler Thromb Vasc Biol 2000; 20(7): 1707-15.
14. Chalimoniuk M. Secretory phospholipase A2 and its role in oxidative stress and inflammation. Postepy Biochem 2012; 58: 204-8.
15. Birrell MA, Maher SA, Dekkak B, et al. Anti-inflammatory effects of PGE2 in the lung: role of the EP4 receptor subtype. Thorax 2015; 70: 740-7.
16. Kanu A, Leffler CW. Arachidonic acid-and prostaglandin E2-induced cerebral vasodilation is mediated by carbon monoxide, independent of reactive oxygen species in piglets. Am J Physiol Heart Circ Physiol 2011; 301: H2482-7.
17. Calabrese V, Mancuso C, Calvani M, et al. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci 2007; 8: 766-75.
18. Chakroborty S, Kim J, Schneider C, West AR, Stutzmann GE. Nitric oxide signaling is recruited as a compensatory mechanism for sustaining synaptic plasticity in Alzheimer's disease mice. J Neurosci 2015; 35: 6893-902.
19. Krischel V, Bruch-Gerharz D, Suschek C, et al. Biphasic effect of exogenous nitric oxide on proliferation and differentiation in skin derived keratinocytes but not fibroblasts. J Invest Dermatol 1998; 111: 286-91.
20. Signorello MG, Segantin A, Leoncini G. The arachidonic acid effect on platelet nitric oxide level. Biochim Biophys Acta 2009; 1791: 1084-92.
21. Cantoni O, Palomba L, Persichini T, et al. Pivotal role of arachidonic acid in the regulation of neuronal nitric oxide synthase activity and inducible nitric oxide synthase expression in activated astrocytes. Methods Enzymol 2008; 440: 243-52.
22. Persichini T, Mastrantonio R, Del Matto S, et al. The role of arachidonic acid in the regulation of nitric oxide synthase isoforms by HIV gp120 protein in astroglial cells. Free Radic Biol Med 2014; 74: 14-20.
23. Mistra AN, Musra M, Singh R. Nitric oxoide: A ubiniquitous signaling molecule with diverse role in plants. Afr J Plant Sci 2011, 5: 57-74.
24. Lu Y, Simpson KL, Weaver KJ, Lin RC. Coexpression of serotonin and nitric oxide in the raphe complex: cortical versus subcortical circuit. Anat Rec 2010, 293: 1954-65.
25. Breard M, Sari MA, Frapart Y, et al. The endogenous neurotransmitter, serotonin, modifies neuronal nitric oxide synthase activities. Free Radic Res 2007; 41: 413-23.
26. Klejbor I, Domaradzka-Pytel B, Ludkiewicz B, et al. The relationships between neurons containing dopamine and nitric oxide synthase in the ventral tegmental area. Folia Histochem Cytobiol 2004; 42: 83-7.
27. Sousa JB, Vieira-Rocha MS, Arribas SM, et al. Endothelial and Neuronal Nitric Oxide Activate Distinct Pathways on Sympathetic Neurotransmission in Rat Tail and Mesenteric Arteries. PLoS One 2015; 10(6): e0129224.
28. Li DP, Chen SR. Nitric oxide stimulates glutamatergic synaptic inputs to baroreceptor neurons through potentiation of Cav2.2-mediated Ca (2+) currents. Neurosci Lett 2014; 567: 57-62.
29. Bossy-Wetzel E, Lipton SA. Nitric oxide signaling regulates mitochondrial number and function. Cell Death Differ 2003; 10: 757-60.
30. Contestabile A, Ciani E. Role of nitric oxide in the regulation of neuronal proliferation, survival and differentiation. Neurochem Int 2004; 45: 903-14.
31. Jaffrey SR, Erdjument-Bromage H, Ferris CD, Tempst P, Snyder SH. Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat Cell Biol 2001; 3: 193-7.
32. Arandarcikaite O, Jokubka R, Borutaite V. Neuroprotective effects of nitric oxide donor NOC-18 against brain ischemia-induced mitochondrial damages: role of PKG and PKC. Neurosci Lett 2015; 586: 65-70.
33. Pham H, Duy AP, Pansiot J, et al. Impact of inhaled nitric oxide on white matter damage in growth-restricted neonatal rats. Pediatr Res 2015; 77: 563-9.
34. Balez R, Ooi L. Getting to NO Alzheimer's disease: Neuroprotection versus neurotoxicity mediated by nitric oxide. Oxid Med Cell Longev 2015; 2015: 278164.
35. Cheng Q, Sedlic F, Pravdic D, et al. Biphasic effect of nitric oxide on the cardiac voltage-dependent anion channel. FEBS Lett 2011; 585: 328-34.
36. Warner DS, Sheng H, Batinić-Haberle I. Oxidants, antioxidants and the ischemic brain. J Exp Biol 2004; 207(Pt 18): 3221-31.
37. Fubini B, Hubbard A. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis. Free Radic Biol Med 2003; 34: 1507-16.
38. Cobb CA, Cole MP. Oxidative and nitrative stress in neurodegeneration. Neurobiol Dis 2015; 84: 4-21.
39. de Lima TM, de Sa Lima L, Scavone C, Curi R. Fatty acid control of nitric oxide production by macrophages. FEBS Lett 2006; 580: 3287-95.
40. Baker PR, Lin Y, Schopfer FJ, et al. Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. J Biol Chem 2005; 280: 42464-75.
41. Vrablik, TL, Watts JL. Polyunsaturated fatty acid derived signaling in reproduction and development: insights from Caenorhabditis elegans and Drosophila melanogaster. Mol Reprod Dev 2013; 80: 244-59.
42. Crupi R, Marino A, Cuzzocrea S. n-3 fatty acids: role in neurogenesis and neuroplasticity. Curr Med Chem 2013; 20: 2953-63.
43. Tamiji J, Crawford DA. The neurobiology of lipid metabolism in autism spectrum disorders. Neurosignals 2010; 18: 98-112.
44. Kurlak LO, Stephenson TJ. Plausible explanations for effects of long chain polyunsaturated fatty acids (LCPUFA) on neonates. Arch Dis Child Fetal Neonatal Ed 1999; 80: F148-54.
45. 2+ channel protein Orai1 in a process that correlates with inhibition of stimulated STIM1 oligomerization. Biochim Biophys 2014; 1841: 1210-6.
46. Gharami K, Das M, Das S. Essential role of docosahexaenoic acid towards development of a smarter brain. Neurochem Int 2015; 89: 51-62.
47. Bazinet RP, Laye S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci 2014; 15: 771-85.
48. Vancassel S, Durand G, et al. Chalon, Plasma fatty acid levels in autistic children. Prostaglandins. Leukot Essent Fatty Acids 2001; 65: 1-7.
49. El-Anary AK, Bacha AG, Al-Ayahdi LY. Impaired plasma phospholipids and relative amounts of essential polyunsaturated fatty acids in autistic patients from Saudi Arabia. Lipids Health Dis 2011; 10: 63.
50. Brigandi SA, Shao H, Qian SY, et al. Autistic children exhibit decreased levels of essential Fatty acids in red blood cells. Int J Mol Sci 2015; 16: 10061-76.
51. Thogersen J, Gadegaard A, Nielsen J, Jensen SK, Petersen C, Keiding SR. Primary formation dynamics of peroxynitrite following photolysis of nitrate. Phys Chem A 2009; 113(39): 10488-94.
52. Yui K, Koshiba M, Nakamura S, Kobayashi Y. Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: a double-blind, placebo-controlled, randomized trial. J Clin Psychopharmacol 2012; 32: 200-6.
53. Yui K, Imataka G, Kawasaki Y, Yamada H. Down-regulation of a signaling mediator in association with lowered plasma arachidonic acid levels in individuals with autism spectrum disorders. Neurosci Lett 2016; 610: 223-8.
54. Chauhan A, Chauhan V, Brown WT, Cohen I. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin--the antioxidant proteins. Life Sci 2004; 75: 2539-49.
55. Lazzaro M, Bettegazzi B, Barbariga M, et al. Ceruloplasmin potentiates nitric oxide synthase activity and cytokine secretion in activated microglia. J Neuroinflammation 2014; 11: 164.
56. Shiva S, Wang X, Ringwood LA, et al. Ceruloplasmin is a NO oxidase and nitrite synthase that determines endocrine NO homeostasis. Nat Chem Biol 2006; 2: 486-93.
57. Ebrahimi-Fakhari D, Sahin M. Autism and the synapse: emerging mechanisms and mechanism-based therapies. Curr Opin Neurol 2015; 28: 91-102.
58. Fossier P, Blanchard B, Ducrocq C, et al. Nitric oxide transforms serotonin into an inactive form and this affects neuromodulation. Neuroscience 1999; 93: 597-603.
59. Soğut S, Zoroğlu SS, Ozyurt H, et al. Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clin Chim Acta 2003; 331: 111-7.
60. Colvin SM, Kwan KY. Dysregulated nitric oxide signaling as a candidate mechanism of fragile X syndrome and other neuropsychiatric disorders. Front Genet 2014; 5: 239.
61. Sweeten TL, Posey DJ, Shankar S, McDougle CJ. High nitric oxide production in autistic disorder: a possible role for interferongamma. Biol Psychiatry 2004; 55: 434-7.
62. Ranjbar A, Rashedi V, Rezaei M. Comparison of urinary oxidative biomarkers in Iranian children with autism. Res Dev Disabil 2014; 35(11): 2751-5.
63. Ghezzo A, Visconti P, Abruzzo PM, et al. Oxidative Stress and Erythrocyte Membrane Alterations in Children with Autism: Correlation with Clinical Features. PLoS One 2013; 8: e66418.
64. Meguid NA, Dardir AA, Abdel-Raouf ER, Hashish A. Evaluation of oxidative stress in autism: defective antioxidant enzymes and increased lipid peroxidation. Biol Trace Elem Res 2011; 143: 58-65.
65. Parellada M, Moreno C, Mac-Dowell K, et al. Plasma antioxidant capacity is reduced in Asperger syndrome. J Psychiat Res 2012; 46: 394-401.
66. Pierce GL, Larocca TJ. Reduced vascular tetrahydrobiopterin (BH4) and endothelial function with ageing: is it time for a chronic BH4 supplementation trial in middle-aged and older adults? J Physiol 2008; 586(Pt 11): 2673-4.
67. Frye RE, DeLatorre R, Taylor HB, et al. Metabolic effects of sapropterin treatment in autism spectrum disorder: a preliminary study. Transl Psychiatry 2013; 3: e237.
68. Frye RE, Huffman LC, Elliott GR. Tetrahydrobiopterin as a novel therapeutic intervention for autism. Neurotherapeutics 2010; 7: 241-9.
69. Danfors T, von Knorring AL, Hartvig P, et al. Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. J Clin Psychopharmacol 2005; 25: 485-9.
70. Klaiman C, Huffman L, Masaki L, Elliott GR. Tetrahydrobiopterin as a treatment for autism spectrum disorders: a double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 2013; 23(5): 320-8.
71. Liddie S, Balda MA, Itzhak Y. Nitric oxide (NO) signaling as a potential therapeutic modality against psychostimulants. Curr Pharm Des 2013; 19: 7092-102.
72. Chakroborty S, Kim J, Schneider C, West AR, Stutzmann GE. Nitric oxide signaling is recruited as a compensatory mechanism for sustaining synaptic plasticity in Alzheimer's disease mice. J Neurosci 2015; 35: 6893-902.
73. Krass M, Wegener G, Vasar E, Volke V. The antidepressant action of imipramine and venlafaxine involves suppression of nitric oxide synthesis. Behav Brain Res 2011; 218: 57-63.
74. Joca SR, Moreira FA, Wegener G. Atypical Neurotransmitters and the Neurobiology of Depression. CNS Neurol Disord Drug Targets 2015; 14: 1001-11.
75. Straub VA, Grant J, O'Shea M, Benjamin PR. Modulation of serotonergic neurotransmission by nitric oxide. J Neurophysiol 2007; 97: 1088-99.
76. Krass M, Wegener G, Vasar E, Volke V. The antidepressant action of imipramine and venlafaxine involves suppression of nitric oxide synthesis. Behav Brain Res 2011; 218: 57-63.
77. Talarowska M, Gałecki P, Maes M, et al. Nitric oxide plasma concentration associated with cognitive impairment in patients with recurrent depressive disorder. Neurosci Lett 2015; 510: 127-31.
78. Beheydt LL, Schrijvers D, Docx L, et al. Psychomotor retardation in elderly untreated depressed patients. Front Psychiatry 2015; 5: 196.
79. Akpinar A, Yaman GB, Demirdas A, Onal S. Possible role of adrenomedullin and nitric oxide in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2013; 46: 120-5.
80. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet 2015; [Epub ahead of print].
81. Leadholm AK, Rothschild AJ, Nielsen J, Bech P, Ostergaard SD. Risk factors for suicide among 34,671 patients with psychotic and non-psychotic severe depression. J Affect Disord 2014; 156: 119-25.
82. Kim YK, Paik JW, Lee SW, et al. Increased plasma nitric oxide level associated with suicide attempt in depressive patients. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1091-6.
83. Oliveira J, Debnath M, Etain B, et al. Violent suicidal behaviour in bipolar disorder is associated with nitric oxide synthase 3 gene polymorphism. Acta Psychiatr Scand 2015; 132: 218-25.
84. Bielau H, Brisch R, Bernard-Mittelstaedt J, et al. Immunohistochemical evidence for impaired nitric oxide signaling of the locus coeruleus in bipolar disorder. Brain Res 2012; 1459: 91-9.
85. Bernstein HG, Keilhoff G, Steiner J, Dobrowolny H, Bogerts B. Nitric oxide and schizophrenia: present knowledge and emerging concepts of therapy. CNS Neurol Disord Drug Targets 2011; 10: 792-807.
86. Karolewicz B, Szebeni K, Stockmeier CA, et al. Low nNOS protein in the locus coeruleus in major depression. J Neurochem 2004; 91: 1057-66.
87. Kittel-Schneider S, Reus M, Meyer A, et al. Multi-level biomarker analysis of nitric oxide synthase isoforms in bipolar disorder and adult ADHD. J Psychopharmacol 2015; 29: 31-8.
88. Fontoura PC, Pinto VL, Matsuura C, et al. Defective nitric oxidecyclic guanosine monophosphate signaling in patients with bipolar disorder: A potential role for platelet dysfunction. Psychosom Med 2012; 74: 873-7.
89. Gałecki P, Maes M, Florkowski A, et al. Association between inducible and neuronal nitric oxide synthase polymorphisms and recurrent depressive disorder. J Affect Disord 2011; 129: 175-82.
90. Chakroborty S, Kim J, Schneider C, West AR, Stutzmann GE. Nitric oxide signaling is recruited as a compensatory mechanism for sustaining synaptic plasticity in Alzheimer's disease mice. J Neurosci 2015; 35: 6893-902.
91. Lin AL, Zheng W, Halloran JJ, Burbank RR, et al. Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer's disease. J Cereb Blood Flow Metab 2013; 33: 1412-21.
92. Luth HJ, Holzer M, Gartner U, Staufenbiel M, Arendt T. Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology. Brain Res 2002; 913(1): 57-67.
93. Rowan MJ, Klyubin I, Wang Q, Anwyl R. Mechanisms of the inhibitory effects of amyloid beta-protein on synaptic plasticity. Exp Gerontol 2004; 9: 1661-7.
94. Obulesu M, Venu R, Somashekhar R. Lipid peroxidation in Alzheimer's disease: emphasis on metal-mediated neurotoxicity. Acta Neurol Scand 2011; 124: 295-301.
95. Kim IK, Lee KJ, Rhee S, et al. Protective effects of peroxiredoxin 6 overexpression on amyloid β-induced apoptosis in PC12 cells. Free Radic Res 2013; 47: 836-46.
96. Godinez-Rubi M, Rojas-Mayorquin AE, Ortuno-Sahagun D. Nitric oxide donors as neuroprotective agents after an ischemic strokerelated inflammatory reaction. Oxid Med Cell Longev 2013; 2013: 297357.
97. Chen Y, Sun J, Fang L, Liu M, et al. Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl-and butyrylcholinesterase inhibitors. J Med Chem 2012; 55: 4309-21.
98. Chegaev K, Federico A, Marini E, et al. NO-donor thiacarbocyanines as multifunctional agents for Alzheimer's disease. Bioorg Med Chem 2015; 23: 4688-98.
99. Feelisch M. The use of nitric oxide donors in pharmacological studies. Naunyn Schmiedebergs Arch Pharmacol 1998; 358: 113-22.
100. Ramirez J, Garnica R, Boll MC, Montes S, Rios C. Low concentration of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients: a pilot study. Schizophr Res 2004; 68: 357-61.
101. Lee BH, Kim YK. Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls. Schizophr Res 2008; 104: 36-43.
102. Nakano Y, Yoshimura R, Nakano H, et al. Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study. Hum Psychopharmacol 2010; 25: 139-44.
103. Minutolo G, Petralia A, Dipasquale S, Aguglia E. Nitric oxide in patients with schizophrenia: the relationship with the severity of illness and the antipsychotic treatment. Expert Opin Pharmacother 2012; 13: 1989.
104. Gonzalez-Liencres C, Tas C, Brown EC, et al. Oxidative stress in schizophrenia: a case-control study on the effects on social cognition and neurocognition. BMC Psychiatry 2014; 14: 268.
105. Carrel D, Hernandez K, Kwon M, et al. Nitric oxide synthase 1 adaptor protein, a protein implicated in schizophrenia, controls radial migration of cortical neurons. Biol Psychiatry 2015; 77: 969-78.
106. Weber H, Klamer D, Freudenberg F, et al. The genetic contribution of the NO system at the glutamatergic post-synapse to schizophrenia: further evidence and meta-analysis. Eur Neuropsychopharmacol 2014; 24: 65-85.
107. Hallak JE, Maia-de-Oliveira JP, Abrao J, et al. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry 2013; 70: 668-76.
108. Maia-de-Oliveira JP, Abrao J, Evora PR, et al. The effects of sodium nitroprusside treatment on cognitive deficits in schizophrenia: a pilot study. J Clin Psychopharmacol 2015; 35: 83-5.